EcoDrugPlus

Cholinergic Receptor, Muscarinic 4a

Ensembl ID : ENSIPUG00000001132
Gene Symbol: CHRM4A
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSIPUG00000019067
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSIPUG00000023668
Gene Symbol: CHRM5B
1 Cross references
189 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSIPUG00000012912
Gene Symbol: CHRNA4B
1 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSIPUG00000013158
Gene Symbol: CHRNA7A
4 Cross references
205 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Beta 2

Ensembl ID : ENSIPUG00000003964
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSIPUG00000013239
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSIPUG00000011290
Gene Symbol: F3A
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSIPUG00000011104
Gene Symbol: F7L
3 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSIPUG00000010966
Gene Symbol: F10
3 Cross references
240 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSIPUG00000001588
Gene Symbol: LOC108257189
2 Cross references
214 Possible Orthologues:

Coiled-Coil Domain Containing 6a

Ensembl ID : ENSIPUG00000014052
Gene Symbol: CCDC6A
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).